166 related articles for article (PubMed ID: 22251314)
21. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
Nixon RM; Müller E; Lowy A; Falvey H
Int J Clin Pract; 2009 May; 63(5):766-75. PubMed ID: 19392925
[TBL] [Abstract][Full Text] [Related]
22. Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension.
White WB; Punzi HA; Murwin D; Koval SE; Davidai G; Neutel JM
J Clin Hypertens (Greenwich); 2006 Sep; 8(9):626-33. PubMed ID: 16957424
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of combination therapy with telmisartan plus amlodipine in patients with poorly controlled hypertension.
Bekki H; Yamamoto K; Sone M; Homma T; Nakata M; Nohara M; Fukami K; Okuda S; Yamagishi S
Oxid Med Cell Longev; 2010; 3(5):342-6. PubMed ID: 21150340
[TBL] [Abstract][Full Text] [Related]
24. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study.
Sharma AM; Davidson J; Koval S; Lacourcière Y
Cardiovasc Diabetol; 2007 Oct; 6():28. PubMed ID: 17910747
[TBL] [Abstract][Full Text] [Related]
25. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
26. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.
Nakayama S; Watada H; Mita T; Ikeda F; Shimizu T; Uchino H; Fujitani Y; Hirose T; Kawamori R
Hypertens Res; 2008 Jan; 31(1):7-13. PubMed ID: 18360012
[TBL] [Abstract][Full Text] [Related]
27. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension.
White WB; Lacourciere Y
J Hypertens; 2004 Oct; 22(10):2035-6; author reply 2036-8. PubMed ID: 15361777
[No Abstract] [Full Text] [Related]
28. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.
Giles TD; Oparil S; Silfani TN; Wang A; Walker JF
J Clin Hypertens (Greenwich); 2007 Mar; 9(3):187-95. PubMed ID: 17341994
[TBL] [Abstract][Full Text] [Related]
29. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.
Brunner HR; Arakawa K
Clin Drug Investig; 2006; 26(4):185-93. PubMed ID: 17163250
[TBL] [Abstract][Full Text] [Related]
30. Maintaining goal blood pressures after switching from olmesartan to other angiotensin receptor blockers.
Saseen JJ; Ghushchyan V; Kaila S; Allen RR; Nair KV
J Clin Hypertens (Greenwich); 2013 Dec; 15(12):888-92. PubMed ID: 24102728
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
[TBL] [Abstract][Full Text] [Related]
32. A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction.
Takagi H; Niwa M; Mizuno Y; Goto SN; Umemoto T;
Hypertens Res; 2013 Jul; 36(7):627-33. PubMed ID: 23344134
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin II receptor blockers for the treatment of heart failure: a class effect?
Hudson M; Humphries K; Tu JV; Behlouli H; Sheppard R; Pilote L
Pharmacotherapy; 2007 Apr; 27(4):526-34. PubMed ID: 17381379
[TBL] [Abstract][Full Text] [Related]
34. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension.
Calvo C; Hermida RC; Ayala DE; Ruilope LM
J Hypertens; 2004 Apr; 22(4):837-46. PubMed ID: 15126927
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database.
Neutel J; Smith DH
J Clin Hypertens (Greenwich); 2003; 5(1):58-63. PubMed ID: 12556655
[TBL] [Abstract][Full Text] [Related]
36. [Despite drug treatment, ever second hypertensive patient with morning blood pressure too high].
MMW Fortschr Med; 2004 Aug; 146(33-34):52. PubMed ID: 15526635
[No Abstract] [Full Text] [Related]
37. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
Oparil S; Williams D; Chrysant SG; Marbury TC; Neutel J
J Clin Hypertens (Greenwich); 2001; 3(5):283-91, 318. PubMed ID: 11588406
[TBL] [Abstract][Full Text] [Related]
38. [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Sidorenko BA; Preobrazhenskiĭ DV; Soplevenko AV; Ivanova NA; Stetsenko TM
Kardiologiia; 2004; 44(1):55-65. PubMed ID: 15029149
[TBL] [Abstract][Full Text] [Related]
39. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
Belsey JD
Curr Med Res Opin; 2008 Feb; 24(2):581-9. PubMed ID: 18198012
[TBL] [Abstract][Full Text] [Related]
40. Palatability of angiotensin II antagonists among nephropathic children.
Meier CM; Simonetti GD; Ghiglia S; Fossali E; Salice P; Limoni C; Bianchetti MG;
Br J Clin Pharmacol; 2007 May; 63(5):628-31. PubMed ID: 17302913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
